SORT BY Relevancy
Design Thinking is a human centered approach to innovation that helps uncover the sweet spot of opportunity where the needs of people, the possibilities of technology and the requirements for business success all converge. The application of the Design Thinking methodology (originating out of Stanford’s d.School) as a new approach to looking at solutions can lead to disruptive innovation in clinical trials for drug development. It allows for designing new ways of working, including the needs, challenges and insights about the complex world we work in.
In this discussion, we introduce the basic principals of Design Thinking and an understanding of how the methodology teaches empathy for the end user (the patients). We explore its ability to reframe questions and unleash innovative thinking as well as the "downside" of creative tension. Most importantly, we address how Design Thinking can drive more successful trials.
Hosted by Valerie Bowling, Executive Director of the Conference Forum, guests include:
Co-Founder, The Helber Group
Co-Founder, The Helber Group
Strategic Innovation Leader, Genentech/Roche
Kate, Jen and Komathi will also be leading a hands-on program, May 11-12 in Boston. For more information, click here.
This show is part of the Leukemia & Lymphoma Society Patient Education Series.
Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D. from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine. His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.
Drs. Christopher Gallen, CEO at SK BioPharmaceuticals and Mitchell Katz, Executive Director, Medical Research Operations at Purdue Pharma, in a candid conversation on navigating the complexities of Global Clinical Trials and addressing topics including: Why global trials? Why are global trials so expensive? How are companies re-thinking global trials? What's happening with global outsourcing? Thoughts on emerging markets and patient recruitment What can we do to help mitigate the risks of global trials?
Our guest on Monday, February 10, 2014 is David Fuehrer. Dave is a two-time testicular cancer survivor and President of CureLauncher, a company he cofounded. Prior to doing so, Dave spent 10 years developing new products across North America, China and Europe for Pfizer, General Electric, Dow and many others.
Dave will share his mission to solve the clinical trial enrollment problem that currently exists in the United States. His company and website connects people to lifesaving medical treatments that they might otherwise be unaware exist. Some of the best medical treatment can be found in clinical trials, but few know or trust them enough to seek them out.
Join us as we discuss the myths and invaluable services CureLauncher and clinical trials provides to patients and the medical community.
This show is part of the Leukemia & Lymphoma Society Patient Education Series. Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D. from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine. His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.
In order to have new drugs to help with cancers and rare diseases, we have to first try them out in Clinical Trials. The design process of clinical trials is somewhat cumbersome and is often inherently controversial. We want to make sure that the trial gives us the information on safety and effectiveness that we will want to know once it goes on the market. At the same time we don’t want to over-complicate the clinical trial process and take too long to approve drugs that are doing well.
Billy Foster is in a clinical trial and has had a good response to the drug he is taking. Through his involvement with programs through the Kidney Cancer Association (KCA) and the American Association for Cancer Research (AACR) he has become aware of built-in disparities in the design of most clinical tri
Join host, Craig H. Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on what it really means to partner with patients in clinical trials.
Jeri Burtchell, Founder, Partners in Research
Regina Holliday, Artist and Medical Advocate
For more information on Jeri's new launch, visit: Healthivibe.com and for Regina walking gallary, google Regina Holliday, walking gallary.
For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.
Join guests Kerri Weingard, ANP, COO, Verified Clinical Trials and Susan Salgado, PhD, Founder, Hospitality Quotient as they identify the barriers and limitations in engaging patients in clinical trials. What we can do about it through communication and service? Hosted by Valerie Bowling, Executive Director, the Conference Forum, this episode addresses one of the hottest topics at the Patients as Partners event scheduled for March 3-4, 2014 in Philadelphia. For more information, visit www.theconferenceforum.org
About our Guests:
Susan Reilly Salgado, PhD founded Hospitality Quotient with Danny Meyer in 2010. Hospitality Quotient offers customized advice and training to inspire, build and sustain a company culture of service in organizations across industries. In addition to her PhD, Susan holds a BS and an MBA from Lehigh University. Susan has also served as an instructor in organizational behavior and business strategy at NYU and as a guest lecturer at Lehigh.
Kerri Weingard is the chief operating officer at Verified Clinical Trials (VCT), a New York-based firm specializing in ensuring the integrity of medical studies and clinical trials by creating a database of research study participants trials. Ms. Weingard, who is a nurse practitioner, holds a master’s degree in science from Stony Brook University. She has conducted over 500 clinical trials as a research coordinator and sub-investigator.
Dr. Ian Thompson is Professor, Glenda and Gary Woods Distinguished Chair in GU Oncology at The University of Texas Health Science Center, San Antonio. Dr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Thompson has published over 400 scientific papers, several dozen book chapters, and has edited five textbooks in medicine and surgery. He currently serves as Vice-Chair of the Early Detection Research Network of the National Cancer Institute and is Chair of the Genitourinary Committee of the Southwest Oncology Group, the largest clinical trials organization supported by the National Cancer Institute. Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 8 years of followup, currently follows over 3,600 men for development of prostate cancer and has been the source of many recent important developments in the early detection of prostate cancer.
Our prostate cancer panels are conducted in association with Prostate Cancer International and Prostate Cancer Foundation.
RSVP here (or) mail email@example.com
Donald Jones, Chief Digital Officer, Scripps Translational Science Institute talks with host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer on what's happening with digital in drug development. Don discusses his thoughts on the evolution of new products with digital and the “digitazation” of tools for clinical trials. He also shares his thoughts on the biggest disruptors in pharma.
Don and Craig will be featured in an interview as well at DPharm: Disruptive Innovations to Advance Clinical Trials on September 11, 2014 in Boston.
Head of Clinical Innovation, R&D
Chief Digital Officer
Scripps Translational Science Institute
Founder & Chairman, Wireless Life Sciences Alliance
The Conference Forum
Join us in a discussion on serving patients in clinical trials.
Making clinical trials more accessible for patients Emerging technologies / iPads and informed consent Disruption Headlines in the news Host:
Craig Lipset, MBA Head of Clinical Innovation, R&D, Pfizer Inc.
Andreas Koester, MD, PhD VP, Clinical Trial Innovation & External Alliances, Janssen
Anthony Costello, CEO, Mytrus
Season 3 of Battling and Beating Cancer gets off to a compelling start by discussing Clinical Trials, Why They Are Safe & Important For Patients. Many patients feel that, by participating in clinical trials they will be used as Guinea pigs. The reality is that, in today's clinical trials, patients are well- monitored and generally receive the standard of care for their disease as well as an additional agent or agents that have demonstrated some degree of effectiveness. Many people are alive today because they participated in clinical trials. Dr. Julie Vose, Chief of the Division of Hematology Oncology and Professor of Medicine, University of Nebraska Medical Center, joins Charlene and Scott and helps to separate the fact from the fiction regarding clinical trials. We also will be joined by Greg Dafoe, a lymphoma survivor and moderator of the NHL Cyberfamily Support Group. Greg will discuss his participation in a clinical trial.
Chicago Blood Cancer Foundation and Lymphoma Coalition have joined forces to bring you this episode of Battling and Beating Cancer.